Post-transplant hepatic veno-occlusive disease: Pathogenesis, diagnosis and treatment

Reviews in Clinical and Experimental Hematology

Volumn 8, Issue 1, 2004, Pages

  Ho, Vincent ^a   Momtaz, Parisa ^a   Didas, Colleen ^a   Wadleigh, Martha ^a   Richardson, Paul ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN III; FIBRINOLYTIC AGENT; GEMTUZUMAB OZOGAMICIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTAGLANDIN E1; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANTICOAGULANT THERAPY; ASCITES; BILIRUBIN BLOOD LEVEL; DISEASE SEVERITY; ENDOTHELIUM CELL; FIBRINOLYTIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; LIVER INJURY; LIVER VEIN OBSTRUCTION; MORTALITY; PORTOSYSTEMIC ANASTOMOSIS; PROGNOSIS; REVIEW; WEIGHT GAIN;

EID: 21944451271     PISSN: 11270020     EISSN: 1825151X     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. McDonald, GB, Sharma, P, Matthews, DE, et al., Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology, 4: 116-22, 1984.
2. McDonald, GB, Hinds, MS, Fisher, LD, et al., Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Int Med, 118: 255-67, 1993. (full text)
3. Bearman, SI, The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood, 85: 3005-20, 1995. (full text)
4. Jones, RJ, Lee, KSK, Beschorner, WE, et al., Venoocclusive disease of the liver following bone marrow transplantation. Transplantation, 44: 778-783, 1987.
5. Blostein, MD, Paltiel, OB, Thibault, A, et al., A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant, 10: 439-443, 1992.
6. Bearman, SI, Anderson, GL, Mori, M, et al., Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol, 11: 1729-36, 1993.
7. Carreras, E, Bertz, H, Arcese, W, et al., Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood, 92: 3599-604, 1998. (full text)
8. McDonald, GB, Venocclusive disease of the liver following marrow transplantation. Marrow Transplantation Reviews, 3: 49-56, 1993.
9. Reiss, U, Cowan, M, McMillan, A, et al., Hepatic Venooclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol, 24: 706-9, 2002.
10. Richardson, PG and Guinan, EC, The pathology, diagnosis and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol, 107: 485-693, 1999.
11. Lee, JL, Gooley, T, Bensinger, W, et al., Venocclusive disease of the liver after high-dose chemotherapy with alkylating agents: incidence, outcome and risk factors. Hepatology, 26: 149A, 1997.
12. Ayash, LJ, Hunt, M, Antman, K, et al., Hepatic venocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol, 8: 1699-1706, 1990.
13. Nevill, TJ, Barnett, MJ, Klingemann, H-G, et al., Regimen-related toxicity of busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol, 9: 1224-32, 1991.
14. Matute-Bello, G, McDonald, GD, Hinds, MS, et al., Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant, 21: 1125-30, 1998.
15. Hagglund, H, Remberger, M, Klaesson, S, et al., Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation (see comments). Blood, 92: 4568-72, 1998. (full text)
16. Ringden, O, Ruutu, T, Remberger, M, et al., A Randomized Trial comparing Busulfan with Total Body Irradiation as Conditioning in Allogeneic Marrow Transplant Recipients With Leukemia: a Report from the Nordic Bone Marrow Transplantation Group. Blood, 83: 2723-2730, 1994. (full text)
17. Styler, MJ, Crilley, P, Biggs, J, Hepatic dysfunction following busulfan and cyclophosphamide myeloblation: a retrospective, multicenter analysis. Bone Marrow Transplant, 18: 171-6, 1996.
18. Rozman, C, Carreras, E, Qian, C, et al., Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant, 17: 75-80, 1996.
19. Grochow, LB. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol, 20: 18-25, 1993.
20. Hassan, M, Oberg, G, Bekassy, AN, et al., Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol, 28: 130-4, 1991.
21. Schuler, U, Schroer, S, Kuhnle, A, et al., Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplantation, 14: 759-765, 1994.
22. Yeager, AM, Wagner, JE, Jr., Graham, ML, et al., Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood, 80: 2425-8, 1992. (full text)
23. McDonald, GB, Slattery, JT, Bouvier, ME, et al., Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood, 101: 2043-2048, 2003. (full text)
24. Hogan, W, Maris, M, Storer, B, et al., Hepatic Injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood, 103: 78-84, 2003.
25. Vaughan, DE, Plavin, SR, and Schafer, AI, PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood, 73: 1213-17, 1989.
26. Fisher, DC, Vredenburgh, JJ, Petros, WP, et al., Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant, 21: 117-22, 1998.
27. Strauer, BE, Brehm, M, Zeus, T, et al., Repair of Infarcted Myocardium by Autologous Intracoronary Mononuclear Bone Marrow Cell Transplantation in Humans. Circulation, in press 2002. (full text)
28. Korbling, M, Katz, RL, Khanna, A, et al., Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med, 346: 738-746, 2002.
29. Soiffer, R, Dear, K, Rabinowe, SN, et al., Hepatic dysfunction follwoing T-cell-depleted allogeneic bone marrow transplantation. Transplantation, 52: 1014-1019, 1991.
30. Moscardo, F, Sanz, GF, and De la Rubia, J, Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34+ positive selection. Bone Marrow Transplant, 27: 983-988, 2001.
31. Moscardo, F, A., U-I, Sanz, GF, et al., Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol, 31: 545-550, 2003.
32. Tack, DK, Letendre, L, Kamath, P, et al., Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant, 28: 895-897, 2001.
33. McDonald, GB, Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzmab ozogamicin (mylotarg (r)). Clin Lymphoma, 2(Suppl 1): S35-49, 2002.
34. Wadleigh, M, Richardson, P, Zahrieh, D, et al., Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102: 1578-1582, 2003. (full text)
35. Sievers, EL, Larson, R, Estey, E, et al., Final report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematopoietic stem cell transplantation. Blood, 100: 89a, 2002.
36. Rajvanshi, P, Shulman, HM, Sievers, EL, et al., Hepatic Sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood, 99: 2310-2314, 2002. (full text)
37. Tse, WT, Beyer, W, Pendleton, JD, et al., Genetic Polymorphisms in glutathione s-transferase and plasminogen activator inhibitor and risk of veno-occlusive disease (VOD). Blood, 96: 390a, 2000.
38. Poonkuzhali, S, Vidya, S, Shaji, RV, et al., Glutathione S-Transferase Gene Polymorphism and Risk of Major Undergoing Allogeneic Bone Marrow Transplantation. Blood, 98: 852a, 2001.
39. Haire, WD, Cavet, J, Pavletic, SZ, et al., Tumor necrosis factor d3 allele predicts for organ dysfunction after allogeneic blood stem cell transplantation (ABSCT). Blood, 96: 584a, 2000.
40. Traber, PG, Chianale, J, and Gumucio, JJ, Physiologic significance and regulation of hepatocellular heterogeneity (see comments). Gastroenterology, 95: 1130-1143, 1988.
41. el Mouelhi, M and Kauffman, FC, Sublobular distribution of transferases and hydrolases associated with glucuronide, sulfate and glutathione conjugation in human liver. Hepatology, 6: 450-456, 1986.
42. Shulman, HM, Gown, AM, and Nugent, DJ, Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol, 127: 549-558, 1987.
43. Shulman, HM, Fisher, LB, Schoch, HG, et al., Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology, 19: 1171-1180, 1994.
44. DeLeve, L, Shulman, HM, and McDonald, GB, Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis, 22: 27-42, 2002.
45. DeLeve, LD, Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology, 24: 830-37, 1996.
46. Bearman, SI, Don't GO to VOD. Blood, (102): 1561a, 2003.
47. Catani, L, Gugliotta, L, Vianelli, N, et al., Endothelium and bone marrow transplantation. Bone Marrow Transplant, 17: 277-280, 1996.
48. Salat, C, Holler, E, Reinhardt, B, et al., Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant, 14: 747-750, 1994.
49. Salat, C, Holler, E, Kolbe, HJ, et al., Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant. Blood, 89: 2184-2188, 1997. (full text)
50. Richardson, P, Krishnan, A, Wheeler, C, et al., Elevation of PAI-1 levels in BMT-associated VOD and changes seen with the use of defibrotide. Blood, 88: 458a, 1996.
51. Richardson, P, Hoppensteadt, D, Elias, A, et al., Elevation of tissue factor pathway inhibitor (TFPI), thrombomodulin (TM) and plasminogen activator inhibitor-1 (PAI-1) levels in stem cell transplant (SCT)-Associated veno-occlusive disease (VOD) and changes seen with the use of defibrotide (DF). Blood, 90: 219a, 1997.
52. Richardson, PG, Hoppensteadt, DA, Elias, AD, et al., Elevation of endothelial stress products and trends seen in patients with severe veno-occlusive disease treated with defibrotide. Thrombosis and Haemostasis, Supplement(August): 628, 1999.
53. Nurnberger, W, Michelmann, I, Burdach, S, et al., Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol, 76: 61-65, 1998.
54. Sato, Y, Asada, Y, Hara, S, et al., Hepatic stellate cells (Ito cells) in veno-occlusive disease of the liver after allogeneic bone marrow transplantation. Histopathology, 34: 66-70, 1999.
55. Collins, PW, Gutteridge, CN, O'Driscoll, A, et al., von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant, 10: 499-506, 1992.
56. Scrobohaci, ML, Drouet, L, Monem-Mansi, A, et al., Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res, 63: 509-519, 1991.
57. Park, YD, Yasui, M, Yoshimoto, T, et al., Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant, 19: 915-920, 1997.
58. Oh, H, Tahara, T, Bouvier, M, et al., Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease of the liver. Bone Marrow Transplant, 22: 675-679, 1998.
59. Harper, PL, Jarvis, J, Jennings, I, et al., Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant, 5: 39-42, 1990.
60. Haire, WD, Ruby, EI, Gordon, BG, et al., Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA, 274: 1289-95, 1995.
61. Faioni, EM, Krachmalnicoff, A, Bearman, SI, et al., Naturally occuring anticoagulants and bone marrow transplantation: Plasma protein C predicts the development of venocclusive disease of the liver. Blood, 81: 3458-3462, 1993.
62. Sudhoff, T, Heins, M, Sohngen, D, et al., Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation. Eur J Haematol, 60: 106-111, 1998.
63. Bianchi, M and Tracey, KJ. The role of TNF in complications of marrow transplantation. Marrow Transplantation Reviews, 3: 57-61, 1993/94.
64. Ferra, C, de Sanjose, S, Gallardo, D, et al., IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica, 83: 1082-1087, 1998.
65. Schots, R, Kaufman, L, Van Riet, I, et al., Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality. Bone Marrow Transplant, 22: 79-85, 1998.
66. Strasser, SI and McDonald, GB, Gastrointestinal and hepatic complications, in Hematopoietic Cell Transplantation (2nd Edition), S.J. Forman, K.G. Blume, and E.D. Thomas, Editors. 1998, Blackwell Scientific Publication.
67. Stockschlaeder, M, Storb, R, Pepe, M, et al., A pilot study of low dose cyclosporin for graft- versus-host prophylaxis in marrow transplantation. Br J Haematol, 80: 49-54, 1992.
68. Christians, U, Spiekermann, K, Bader, A, et al., Cyclosporine metabolite pattern in blood from patients with acute GVHD after BMT. Bone Marrow Transplant, 12: 27-33, 1993.
69. Thaler, M, Pastiaka, B, Shawker, TH, et al., Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med, 108: 88-100, 1988.
70. Carreras, E, Granena, A, M., N, et al., On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol, 66: 77-80, 1993.
71. Brown, BP, Abu-Yousef, M, Farner, R, et al., Doppler sonography: A noninvasive method for evaluation of hepatic venocclusive disease. AJR, 154: 721-724, 1990.
72. Hosoki, T, Kuroda, C, Tokunaga, K, et al., Hepatic venous outflow obstruction: Evaluation with pulsed duplex sonography. Radiology, 170: 733-737, 1989.
73. Nicolau, C, Concepcio, B, Carreras, E, et al., Sonographic diagnosis and hemodynamic correlation in veno-occlusive disease of the liver. J Ultrasound Med, 12: 437-440, 1993.
74. Sonneveld, P, Lameris, JS, Cornelissen, J, et al., Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment. Bone Marrow Transplant, 21: 731-734, 1998.
75. Carreras, E, Granena, A, Navasa, M, et al., Transjugular liver biopsy in BMT. Bone Marrow Transplant, 11: 21-26, 1993.
76. Shulman, HM, Gooley, T, Dudley, MD, et al., Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation, 59: 1015-1022, 1995.
77. Essell, JH, Schroeder, MT, Harman, GS, et al., Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 128 (12 Pt 1): 975-81, 1998. (full text)
78. Ohashi, K, Tanabe, J, Watanabe, R, et al., The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol, 64: 32-38, 2000.
79. Ruutu, T, Eriksson, B, Remes, K, et al., Ursodiol prevention of hepatic complications in allogeneic stem cell transplantation: results of a prospective, randomized, placebo-controlled trial. (Abstract). Bone Marrow Transplant, 23: 756, 1999.
80. Teicher, BA, Crawford, JM, Holden, SA, et al., Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide. Cancer, 62: 1275-1281, 1988.
81. DeLeve, LD, Glutathione defense in non-parenchymal cells. Semin Liver Dis, 18: 403-413, 1998.
82. Jonas, CR, Puckett, AB, Jones, DP, et al., Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr, 72: 181-189, 2000. (full text)
83. Ringden, O, Remberger, M, Lehmann, S, et al., N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant, 25: 993-996, 2000.
84. Goringe, AP, Brown, S, O'Callaghan, U, et al., Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant, 21: 829-832, 1998.
85. Attal, M, Huguet, F, and Rubie, H, Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood, 79: 2834-2840, 1992. (full text)
86. Bearman, SI, Hinds, MS, and Wolford, JL, A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant, 5: 407-411, 1990.
87. Marsa-Vila, L, Gorin, NC, and Laporte, JP, Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. European Journal of Haematology, 47: 346-352, 1991.
88. Forrest, DL, Thompson, K, Dorcas, VG, et al., Low Molecular Weight Heparin for the prevention of veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant, 31: 1143-1149, 2003.
89. Lee, JH, Lee, KH, Choi, JS, et al., Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment. J Korean Med Sci, 11: 118-126, 1996. (full text)
90. Or, R, Nagler, A, Shpilberg, O, et al., Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation, 61: 1067-1071, 1996.
91. Gluckman, E, Jolivet, I, and Scrobohaci, ML, Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol, 74: 277-281, 1990.
92. Bearman, SI, Shen, D, Hinds, MS, et al., A phase 1/2 study of prostaglandin E1 for the prevention of hepatic venocclusivedisease after bone marrow transplantation. Br J Haematol, 84: 724-730, 1993.
93. Bearman, SI, Shuhart, MC, Hinds, MS, et al., Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation. Blood, 80: 2458-2462, 1992. (full text)
94. Leahey, AM and Bunin, NJ, Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant, 17: 1101-1104, 1996.
95. Bearman, SI, Lee, JL, Baron, AE, et al., Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood, 89: 1501-1506, 1997. (full text)
96. Haire, WD, Stephens, LC, and Ruby, EI, Antithrombin III (AT3) treatment of organ dysfunction during bone marrow transplantation (BMT) - results of a pilot study. Blood, 88: 458a (abstract), 1996.
97. Ibrahim, A, Pico, JL, Maraninchi, D, et al., Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1. Bone Marrow Transplant (Suppl), 7: 53, 1991.
98. Bianchi, G, Barone, D, Lanzarotti, E, et al., Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Europ J Pharmacol, 238: 327-334, 1993.
99. Eissner, G, Multhoff, G, Gerbitz, A, et al., Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood, 100: 334-340, 2002. (full text)
100. Bracht, F and Schror, K, Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochemical and Biophysical Research Communications, 200: 933-936, 1994.
101. Mitsiades, C, Richardson, P, Menon, K, et al., Defibrotide has Anti-Neoplastic Activity Against Multiple Myeloma: Clinical Implications for the Incorporation of Defibrotide in Cytoxic Chemotherapeutic Regimens. Blood, 102: 693a, 2003.
102. Palmer, KJ and Goa, KL, Defibrotide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs, 45: 259-294, 1993.
103. Berti, F, Rossoni, G, Biasi, G, et al., Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins. Prostaglandins, 40: 337-350, 1990.
104. Coccheri, S and Biagi, G, Defibrotide. Cardiovascular Drug Review, 9: 172-196, 1991.
105. Fareed, J, Modulation of endothelium by heparin and related polyelectrolytes., in Advances in Vascular Pathology 1997, A. Nicolaides and S. Novo, Editors. 1997, Elsevier Science B.V.: Amsterdam.
106. ìZhou, Q, Chu, X, and Ruan, C, Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thrombosis and Hemostasis, 71: 507-510, 1994.
107. Coccheri, S, Biagi, G, Legnani, C, et al., Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol, 35: 151-156, 1988.
108. Ulutin, ON, Antithrombotic effect and clinical potential of defibrotide. Sem Thrombosis and Hemostasis, 19: 186-191, 1993.
109. Jamieson, A, Alcock, P, and Tuffin, DP, The action of polyanionic agents defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat. Fibrinolysis, 10: 27-35, 1996.
110. Bonomini, V, Vangelista, A, and Frasca, GM, A new antithrombotic agent in the treatment of acute renal failure due to hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura. Nephron, 37: 144, 1984 (letter).
111. ìViola, F, Marubini, S, Coccheri, G, et al., Improvement of walking distance by defibrotide in patients with intermittent claudication: results of a randomized, placebo-controlled study (the DICLIS study). Thrombosis and Haemostasis, 83: 672-7, 2000.
112. Falanga, A, Marchetti, M, Vignoli, A, et al., Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells. Blood, 94(10): 146a, 1999.
113. Falanga, A, Marchetti, M, Vignoli, A, et al., Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cell macro- and micro-vessels. Blood, 96: 53a, 2000.
114. Falanga, A, Vignoli, A, Marchetti, M, et al., Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia, 17: 1636-1642, 2003.
115. Richardson, PG, Elias, AD, Krishnan, A, et al., Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood, 92: 737-744, 1998. (full text)
116. Abecasis, M, Ferreira, I, Guimaraes, A, et al., Defibrotide as salvage therapy for hepatic veno-occlusive disease (VOD). Bone Marrow Transplant, 23 (Supplement 1): 749 (abstract), 1999.
117. Salat, C, Pihusch, R, Fries, S, et al., Successful treatment of veno-occlsive disease with defibrotide - a report of two cases. Bone Marrow Transplant, 23(Supplement 1): 757 (abstract), 1999.
118. Zinke, W, Neumeister, P, and Linkesch, W. Defibrotide - an approach in the treatment of severe veno-occlusive disease? Bone Marrow Transplant, 23 (Suppl 1): 760 (abstract), 1999.
119. Jenner, MJ, Micallef, IN, Rohatiner, AZ, et al., Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide.(In Process Citation). Med Oncol, 17(4): 333-6, 2000.
120. Chopra, R, Eaton, JD, Grassi, A, et al., Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. British Journal of Haematology, 111: 1122-1129, 2000.
121. Richardson, P, Soiffer, R, Antin, JH, et al., Defibrotide Appears Effective and Safe in a Phase II, Randomized Study of Patients with Severe Veno-Occlusive Disease and Multi-System Organ Failure Post Stem Cell Transplantation. Blood, 100(11): 112a, 2002.
122. Richardson, P, Murakami, C, Jin, Z, et al., Multi-Institutional Use of Defibrotide in 88 Patients Post Stem Cell Transplant With Severe Veno-Occlusive Disease and Multi-System Organ Failure; Response Without Significant Toxicity In a High Risk Population and Factors Predictive of Outcome. Blood, 100(13): 4337-43, 2002. (full text)
123. Kaleelrahman, M, Eaton, JD, Lemming, D, et al., Role of plasminogen activator inhibitor (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). Hematology, 8(2): 91-5, 2003.
124. Versluys, B, Bhattacharaya, R, Steward, C, et al., Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood, 103(5): 1968, 2004. (full text)
125. Richardson, P, Warren, D, Momtaz, P, et al., Multi-Institutional Phase II Randomized Dose Finding Study of Defibrotide (DF)in Patients (pts) with Severe Veno-Occlusive Disease (VOD) and Multi-System Organ Failure (MOF) Post Stem Cell Transplantation (SCT): Promising Response Rate without Significant Toxicity in a High Risk Population. Blood, 98(11 (1)): 853a, 2001.
126. Chanlandon, Y, Roosnek, E, Helg, C, et al., Efficient Prophylaxis with Defibrotide for Hepatic Veno-Occlusive Disease (VOD) after Allogeneic Stem Cell Transplantation (SCT). Blood, 100(11): 111a, 2002.
127. Schlitt, HJ, Tischler, HJ, Ringe, B, et al., Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation - clinical and immunological considerations. Bone Marrow Transplant, 16: 473-8, 1995.
128. Fried, MW, Connaghan, DG, Sharma, S, et al., Trans jugular intrahepatic protosystemic shunt for the management of severe venocclusive disease following bone marrow transplantation. Hepatology, 24: 588-591, 1996.
129. Smith, FO, Johnson, MS, Scherer, LR, et al., Transjugular intrahepatic portosystemic shunting (TIPS) for the treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant, 18: 643-646, 1996.
130. Alvarez, R, Banares, R, Casariego, J, et al., Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation. Gastroenterol Hepatol, 23(4): 177-80, 2000.
131. Tefferi, A, Kumar, S, Wolf, R, et al., Charcoal hemofiltration for hepatic veno-occulsive disease after hematopoietic stem cell transplantatio.n Bone Marrow Transplant, 28(10): 997-9, 2001.